Measurement of factor IX activity in plasma-derived and recombinant concentrates: Insights from thrombin generation and activation-based assays

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 1, 2014, Pages 62-70

  Yu, Y ^a   Millar, C M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

DNA recombinant proteins; Factor IX; Hemophilia B; Plasma; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR CONCENTRATE; CHROMOGENIC SUBSTRATE; PLASMA DERIVED BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; HEMOPHILIA B; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN PROCESSING; THROMBOGENICITY; BLOOD; DNA RECOMBINANT PROTEINS; ENZYME LINKED IMMUNOSORBENT ASSAY; FACTOR IX; HEMOPHILIA B; METABOLISM; PLASMA;

DNA RECOMBINANT PROTEINS; FACTOR IX; HEMOPHILIA B; PLASMA; THROMBIN;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR IX; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS; THROMBIN;

EID: 84891900253     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12452     Document Type: Article

References (26)

1. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
2. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203.
3. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
4. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73.
5. Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995; 35: 319-23.
6. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
7. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, Hemker HC, Negrier C. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
8. Ahnstrom J, Andersson HM, Canis K, Norstrom E, Yu Y, Dahlback B, Panico M, Morris HR, Crawley JT, Lane DA. Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue. Blood 2011; 117: 6685-93.
9. Barrowcliffe TW. Insights from factor IX activation studies with chromogenic assays: implications of disparate product results. Haemophilia 2010; 16(Suppl. 6): 9-12.
10. Bond M, Jankowski M, Patel H, Karnik S, Strang A, Xu B, Rouse J, Koza S, Letwin B, Steckert J, Amphlett G, Scoble H. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-17.
11. Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 115:2569-77.
12. Makino Y, Omichi K, Kuraya N, Ogawa H, Nishimura H, Iwanaga S, Hase S. Structural analysis of N-linked sugar chains of human blood clotting factor IX. J Biochem 2000; 128: 175-80.
13. Griffith MJ, Monroe DM, van Cott KE, Walker A, Waugh S, Kumar A, Drohan WN. N-Glycan sialylation is important for in vivo recovery of recombinant factor IX. J Thromb Haemost 2007; 5(Suppl. 2): 1-2.
14. Gurewich V, Nunn T, Lipinski B. Activation of intrinsic or extrinsic blood coagulation in experimental venous thrombosis and disseminated intravascular coagulation: pathogenetic differences. Thromb Res 1979; 14: 931-40.
15. Fuchs HE, Trapp HG, Griffith MJ, Roberts HR, Pizzo SV. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984; 73: 1696-703.
16. Duchemin J, Pan-Petesch B, Arnaud B, Blouch MT, Abgrall JF. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008; 99: 767-73.
17. Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. J Biol Chem 1980; 255: 5703-7.
18. Marlar RA, Kleiss AJ, Griffin JH. An alternative extrinsic pathway of human blood coagulation. Blood 1982; 60: 1353-8.
19. Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh Suppl 1965; 17: 35-44.
20. Chavin SI, Weidner SM. Blood clotting factor IX. Loss of activity after cleavage of sialic acid residues. J Biol Chem 1984; 259: 3387-90.
21. Arruda VR, Hagstrom JN, Deitch J, Heiman-Patterson T, Camire RM, Chu K, Fields PA, Herzog RW, Couto LB, Larson PJ, High KA. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-8.
22. Preston RJ, Rawley O, Gleeson EM, O'Donnell JS. Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. Blood 2013; 121: 3801-10.
23. Atoda H, Yokota E, Morita T. Characterization of a monoclonal antibody B1 that recognizes phosphorylated Ser-158 in the activation peptide region of human coagulation factor IX. J Biol Chem 2006; 281: 9314-20.
24. Moore KL. The biology and enzymology of protein tyrosine O-sulfation. J Biol Chem 2003; 278: 24243-6.
25. Geng Y, Verhamme IM, Messer A, Sun MF, Smith SB, Bajaj SP, Gailani D. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem 287:38200-9.
26. Orlova NA, Kovnir SV, Vorobiev II, Gabibov AG. Coagulation factor IX for hemophilia B therapy. Acta Naturae 2012; 4: 62-73.